Moderna（MRNA）在今日夜盘交易中大幅上涨6.68%，引起了市场的广泛关注。
消息面上，公司近日公布了其mRNA汉坦病毒疫苗的一期临床试验积极数据，该疫苗显示出良好的耐受性，并在所有测试剂量组中均诱导出了强劲的抗体反应，这验证了其mRNA技术平台在应对多种病毒性疾病方面的强大能力。此外，公司发布的一季度财务报告显示，营收达到3.89亿美元，大幅超出市场分析师普遍预期的2.28亿美元。与此同时，其在研的mRNA个性化肿瘤治疗性疫苗EVM16的首次人体试验数据也表现积极。基于这些积极进展，瑞银（UBS）上调了对该公司的目标价。多重利好因素共同作用，形成了强劲的上涨动力。
这些来自研发管线与财务表现的积极信号，显著增强了投资者对Moderna在mRNA领域技术领先地位及未来增长潜力的信心，从而推动了股价在夜盘时段走强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.